Development of Novel Protocol for Preclinical Monitoring the Release of Adjuvants Encapsulated Mucosal Delivery Carriers
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artículo científico |
| Lingua: | en |
| Pubblicazione: |
Instituto Finlay
2015
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866814694939951104 |
|---|---|
| author | Mohamed Ibrahim-Saeed |
| author_facet | Mohamed Ibrahim-Saeed |
| contents | Development of Novel Protocol for Preclinical Monitoring the Release of Adjuvants Encapsulated Mucosal Delivery Carriers Mohamed Ibrahim-Saeed Abd Rahaman-Omar Mohd Zobir-Hussein Isam Mohamed-Elkhidir Samer Hussein-Al-Ali Mothanna Sadiq-Al-Qubaisi Zamberi Sekawi Salud Nano adjuvant mucosal vaccines delivery carriers This work contributes in vaccines down-stream process by introducing a novel platform for in-vitro monitoring of vaccine-adjuvant delivery profile as a crucial preclinical optimizing step in mucosal vaccines. Nano and micro particles of Calcium phosphate (Cap) vaccine-adjuvant were encapsulated in Chitosan and Alginate polymeric carriers. Adjuvants release profiles monitored in a permeable bag at 37°C, pH 2, incubated in isotonic buffer for 96 hours. The released Calcium in the outer buffer was monitored and compared in-addition to the carrier’s swelling and biophysical properties. The adjuvants and carriers did not interfere with the proliferation of cultured hepatocytes an indicator of their safe use; Chitosan’s viscosity and swelling were higher than Alginate. Chitosan’s Zeta-potential was significantly high positive, while Cap and Alginate were negative. The prepared CaP and Chitosan particles were in nano-size, while the ready-made CaP adjuvant and Alginate were in micro-size using zeta-seizer and scanning electron-micrograph. The release of nano-size particle was in ascending, extended and controlled manner compared to micro-size adjuvant. Moreover, nano-adjuvant release profile from Chitosan was superior compared to Alginate. The core controlling factors in vaccine-adjuvant sustained release includes; smaller adjuvant particles (nano-size), carrier’s low swelling, high viscosity and importantly carrier-adjuvant entrapment reversibility. Chitosan offers sustained ascending superior capacity in releasing Nano-Cap adjuvant. This novel in-vitro pre-clinical study answer a crucial downstream preparative step for optimizing mucosal vaccines before their direct routine in-vivo trial on animal regardless of adjuvant’s particle size or delivery kinetics. 2015 artículo científico 1025-0298 https://www.redalyc.org/articulo.oa?id=203443342004 en http://www.redalyc.org/revista.oa?id=2034 VacciMonitor application/pdf Instituto Finlay VacciMonitor (Cuba) Num.3 Vol.24 |
| format | Artículo científico |
| id | redalyc_203443342004 |
| language | en |
| publishDate | 2015 |
| publisher | Instituto Finlay |
| spellingShingle | Development of Novel Protocol for Preclinical Monitoring the Release of Adjuvants Encapsulated Mucosal Delivery Carriers Mohamed Ibrahim-Saeed Salud Nano adjuvant mucosal vaccines delivery carriers Development of Novel Protocol for Preclinical Monitoring the Release of Adjuvants Encapsulated Mucosal Delivery Carriers Mohamed Ibrahim-Saeed Abd Rahaman-Omar Mohd Zobir-Hussein Isam Mohamed-Elkhidir Samer Hussein-Al-Ali Mothanna Sadiq-Al-Qubaisi Zamberi Sekawi Salud Nano adjuvant mucosal vaccines delivery carriers This work contributes in vaccines down-stream process by introducing a novel platform for in-vitro monitoring of vaccine-adjuvant delivery profile as a crucial preclinical optimizing step in mucosal vaccines. Nano and micro particles of Calcium phosphate (Cap) vaccine-adjuvant were encapsulated in Chitosan and Alginate polymeric carriers. Adjuvants release profiles monitored in a permeable bag at 37°C, pH 2, incubated in isotonic buffer for 96 hours. The released Calcium in the outer buffer was monitored and compared in-addition to the carrier’s swelling and biophysical properties. The adjuvants and carriers did not interfere with the proliferation of cultured hepatocytes an indicator of their safe use; Chitosan’s viscosity and swelling were higher than Alginate. Chitosan’s Zeta-potential was significantly high positive, while Cap and Alginate were negative. The prepared CaP and Chitosan particles were in nano-size, while the ready-made CaP adjuvant and Alginate were in micro-size using zeta-seizer and scanning electron-micrograph. The release of nano-size particle was in ascending, extended and controlled manner compared to micro-size adjuvant. Moreover, nano-adjuvant release profile from Chitosan was superior compared to Alginate. The core controlling factors in vaccine-adjuvant sustained release includes; smaller adjuvant particles (nano-size), carrier’s low swelling, high viscosity and importantly carrier-adjuvant entrapment reversibility. Chitosan offers sustained ascending superior capacity in releasing Nano-Cap adjuvant. This novel in-vitro pre-clinical study answer a crucial downstream preparative step for optimizing mucosal vaccines before their direct routine in-vivo trial on animal regardless of adjuvant’s particle size or delivery kinetics. 2015 artículo científico 1025-0298 https://www.redalyc.org/articulo.oa?id=203443342004 en http://www.redalyc.org/revista.oa?id=2034 VacciMonitor application/pdf Instituto Finlay VacciMonitor (Cuba) Num.3 Vol.24 |
| title | Development of Novel Protocol for Preclinical Monitoring the Release of Adjuvants Encapsulated Mucosal Delivery Carriers |
| topic | Salud Nano adjuvant mucosal vaccines delivery carriers |
| url | https://www.redalyc.org/articulo.oa?id=203443342004 |